WikiMD is the world's largest medical encyclopedia with
28,899 pages, 4,107,258 edits & 35,688,120 views.
Ofatumumab
Information about Ofatumumab
Ofatumumab is a recombinant human monoclonal antibody to CD20 a cell surface antigen found on pre-B and mature B lymphocytes and which is approved for use in resistant chronic lymphocytic leukemia.
Liver safety of Ofatumumab
Ofatumumab therapy has not been associated with serum enzyme elevations during therapy or to cases of idiosyncratic, clinically apparent liver injury. However, ofatumumab has potent immunosuppressive activity and its use has been associated with cases of reactivation of inactive or previously resolved hepatitis B which can be severe and can result in fatality.
Mechanism of action of Ofatumumab
Ofatumumab (oh” fa toom’ ue mab) is a human monoclonal IgG1 antibody to the cell surface antigen CD20 (also known as human B lymphocyte restricted differentiation antigen: Bp35), which is found on mature B cells as well as 90% of neoplastic B cell such as occur in chronic lymphocytic leukemia. CD20 is not present on pro-B cells, hematopoietic stem cells, normal plasma cells or other normal lymphocytes, circulating cells or tissues. Engagement of ofatumumab with CD20 leads to B cell lysis and depletion of circulating and tissue B cells for an extended period, up to 6 to 8 months. There is an accompanying mild decrease in IgM, but no change in IgG or IgA levels.
FDA approval information for Ofatumumab
Ofatumumab was approved for use in previously treated, resistant chronic lymphocyte leukemia United States in 2009.
Dosage and administration for Ofatumumab
Ofatumumab is available in liquid solution in single use vials of 100 and 1000 mg (20 mg/mL) under the brand name Arzerra. The dose and regimen varies by indication, but it is usually given intravenously in 300 to 2000 mg amounts in 28 day cycles.
Side effects of Ofatumumab
Common side effects include infusion reactions, chills, fever, nausea, diarrhea, fatigue, dyspnea, cough, bronchitis, pneumonia, skin rash, neutropenia and infections. Less common, but potentially severe side effects include cutaneous reactions (Stevens Johnson syndrome), tumor lysis syndrome, prolonged neutropenia, thrombocytopenia and anemia. Because of the potential severity of infusion reactions, premedication with antihistamines, acetaminophen and corticosteroids is recommended, and ofatumumab should be administered under close medical observation.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Ofatumumab
- GoodRx compare cost & coupons for Ofatumumab
- Find the lowest cost of Ofatumumab
- Search for Coupons for Ofatumumab
Reviews for Ofatumumab
Learn more about Ofatumumab
- Dailymed label info
- Scientific articles
- Drug portal Ofatumumab
- toxicity info on Ofatumumab
- FDA Ofatumumab
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Ofatumumab is a stub.
If you are a healthcare professional familiar with the topic Ofatumumab, or
A subject matter expert or authority on Ofatumumab, you can help us.
About | Mission | Paid editors welcome!
| Ofatumumab is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP* |
